How HGH Replacement Actually Works in Plain English

What HGH actually is

Human growth hormone is a single-chain peptide of 191 amino acids, produced by specialized cells (somatotrophs) in the anterior pituitary gland. The pharmaceutical version sold as Norditropin, Genotropin, Humatrope, Omnitrope, and several others is somatropin — recombinant human growth hormone produced in bacterial or mammalian cell culture, structurally identical to the natural human protein.

One historical note worth knowing: before recombinant technology, HGH was extracted from cadaver pituitaries. That practice ended in 1985 after a small number of recipients developed Creutzfeldt-Jakob disease from contaminated extracts. Every modern HGH product is recombinant and free of that risk — but the pre-1985 history is why HGH manufacturing and distribution have been so tightly regulated in the decades since.

How natural growth hormone actually works

Your pituitary releases GH in pulses, not continuously. The largest pulses happen during the first few hours of sleep (during slow-wave sleep specifically); smaller pulses follow exercise, fasting, and certain meal patterns. Between pulses, GH levels drop to very low values. This pulsatile rhythm is the natural pattern your body is calibrated for.

Once GH is released, it does two things:

• Acts directly on tissues — on bone, muscle, fat cells, and others — through the GH receptor.
• Stimulates the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 then circulates and mediates many of the downstream effects most people associate with "growth hormone" — muscle protein synthesis, tissue repair, body composition effects.

So when people talk about "GH effects," they're often really talking about IGF-1 effects. Blood IGF-1 levels are the most-used surrogate marker for clinical GH activity because GH itself fluctuates so rapidly that single measurements are nearly useless.

Natural daily GH output in healthy adults is roughly equivalent to 0.4-1.0 mg, which works out to about 1.2-3 IU using the standard conversion of 1 IU = approximately 0.33 mg. Production peaks in adolescence and declines steadily through adulthood. By 60, total daily output may be 30-50% of what it was at 25 — the basis of the "somatopause" framing some longevity communities use.

What direct HGH injection actually does

Injected HGH bypasses the entire secretion machinery. You're not signaling your pituitary to release more — you're putting somatropin directly into the bloodstream. The pituitary contribution to circulating GH actually goes down during HGH replacement because the brain detects elevated GH and reduces its own GHRH signaling (negative feedback).

Pharmacokinetically, injected somatropin has a short plasma half-life (around 2-3 hours) but a much longer biological effect because of IGF-1 elevation. The IGF-1 generated downstream stays elevated for many hours after a single injection, which is why once-daily dosing is the clinical standard.

The mechanism difference between HGH and secretagogues is fundamental: HGH delivers a sustained, non-pulsatile signal; secretagogues amplify the natural pulses. Whether sustained or pulsatile delivery is better long-term is one of the genuine open questions in this space.

What "1-2 IU per day" actually means

The 1-2 IU daily framework comes up constantly in longevity-focused HGH discussions. A quick reality check on what those numbers mean.

1 IU ≈ 0.33 mg somatropin. So 1-2 IU per day is approximately 0.33-0.66 mg.

For context, compare to other dosing contexts:

• Natural daily GH output in healthy adults: roughly 1-3 IU equivalent.
• Adult growth hormone deficiency (AGHD) treatment: typically titrated to 0.2-0.6 mg/day based on IGF-1 response and tolerability. The 1-2 IU range sits in the upper end of this clinical window.
• Bodybuilding / performance use: 4-10+ IU per day. Supraphysiologic by a wide margin.
• Acromegaly (pathologic GH excess from a pituitary tumor): unregulated, often equivalent to 10-30 IU/day.

The 1-2 IU framework is calibrated to push blood IGF-1 to the upper-normal range for the patient's age (a common target is around 200-250 ng/mL in older adults). It's a "restorative" framing — replace the decline back to youthful levels, don't exceed them. Whether that's the right strategy for longevity is contested; whether it's safer than higher doses is much less contested.

The regulatory landscape (US)

This is where HGH is most distinct from anything else in the GH-axis category.

HGH is a Schedule III controlled substance in the US under the Controlled Substances Act when used for any indication other than FDA-approved ones. The FDA-approved adult indications are:

• Adult growth hormone deficiency (AGHD) confirmed by stimulation testing.
• Wasting syndrome in HIV/AIDS patients.
• Short bowel syndrome.
• Several pediatric indications.

That's it. Prescribing HGH for "anti-aging," athletic performance, body composition optimization in a non-deficient patient, or longevity is off-label and federally illegal under 21 USC § 333(e), with penalties up to 5 years imprisonment and substantial fines for both prescriber and patient in some interpretations. This is much harsher than typical off-label prescription law in the US, and HGH is uniquely covered this way.

In practice, enforcement against individual patients is rare; enforcement against clinics openly advertising HGH for anti-aging has happened. The legal landscape is genuinely different from the GLP-1 class, from research peptides, and from any other compound discussed elsewhere on this site.

How the cost structure works

Legitimate, prescribed HGH for adult growth hormone deficiency in the US runs $1,500-3,500 per month at 1-2 IU/day pricing through major brand pens (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope). Insurance covers it for diagnosed AGHD. Without insurance, even at low doses, the monthly cost is substantial.

For off-label use without insurance coverage, patients sometimes turn to:

• International pharmacies — lower prices but legal exposure on importation.
• Compounding pharmacies — varying availability and legal status.
• Gray market sources — legally and quality-wise problematic.

For comparison, research-grade GHRP/ipamorelin protocols can run $50-150 per month; tesamorelin off-label is in between. The cost gap is one of the central practical reasons people consider secretagogues at all.

Why secretagogues exist as alternatives

If HGH works directly and consistently, why is there a whole class of secretagogues at all?

Three reasons:

1. Mechanism preference. Some clinicians and patients prefer working with the body's natural pulsatile rhythm rather than overriding it. The theoretical safety argument is that pulsatile GH may produce fewer long-term side effects than sustained elevation — less insulin resistance, less aggressive IGF-1 elevation, lower receptor desensitization. The evidence for this preference is largely mechanistic rather than from controlled head-to-head outcome trials.

2. Regulatory accessibility. Tesamorelin is FDA-approved (Egrifta) for HIV-associated lipodystrophy and can be prescribed off-label in some clinical contexts without HGH's Schedule III restriction. Research-grade GHRPs exist in a different regulatory category entirely (research use only). Both are more accessible than legitimate HGH for most people pursuing this.

3. Cost. Even off-label, a tesamorelin or GHRP protocol typically costs a fraction of HGH at therapeutic doses.

None of these reasons mean secretagogues "work the same" as HGH — they don't, particularly in the magnitude they can achieve. They're alternatives because they're more accessible and represent a different bet about how to optimize the GH axis. See the comparison article for the side-by-side.

The honest read

HGH replacement is the mechanically simplest GH-axis intervention — inject the hormone, let the body respond — and the most regulated, the most expensive, and the most legally fraught for non-deficient adults in the US. For patients with diagnosed adult growth hormone deficiency, it's the standard of care with substantial supporting evidence. For longevity-focused or body-composition-focused use in non-deficient adults, the legal exposure is real, the cost is substantial, and the long-term safety data outside the AGHD population is genuinely thin.

Understanding what HGH is and how it works is necessary background for any informed comparison with tesamorelin or GHRP alternatives. The comparison itself — mechanism, magnitude, evidence, cost, regulatory status — is the subject of the companion piece, and the longevity-specific question is the subject of the longevity deep dive.